Nitrendipine/atenolol combination tablets anti-hypertension treatment in community healthcare

Effectiveness and safety for primary hypertension patients with nitrendipine/atenolol combination tablets in community

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001645

Enrollment

Unknown

Registered

2011-09-28

Start date

2011-10-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension

Interventions

treatment group:The enrolled patients aged 18-70 will be treated with nitrendipine/atenolol combination tablets for 6 months(some of them will be treated for 12 months). The initial dose comprised two

(to be continued): If the blood pressure is higher than that of baseline at the end of the second week, the drugs may increase to 3 tablets(taking an additional tablet of drug at about 18:00 pm). If t

(to be continued): If the blood pressure are poor controlled (= 140/90 mmHg) at the end of the second month, the patients may take other antihypertensive drugs (other CCB and ß-blockers are not allowe

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) 18-70 years old, both male and female; 2) Patients diagnosed with primary hypertension,having mean systolic blood pressure >=140 mmHg and =90mmHg and <110 mmHg without antihypertensive therapy; 3) Gave written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1) Unstable angina,cerebrovascular accident,myocardial infarction,or heart failure(left ventricular ejection fraction11mmol/L), or T2DM with complications (nephrosis,peripheral neuropathy); 5) Gastroenteropathy, or gastrointestinal surgery possibly influencing drug absorption; 6) Thyroid dysfunction; 7) Second degree atrioventricular block(II AVB) or III AVB, sick sinus syndrome, or heart rate 2 times the upper limit of normal values, or serum creatinine >150umol/L; 10) Pregnancy or lactation women; 11) Allergic to calcium antagonist and/or beta-blocker; 12) To participate other drug trial at the same time or within 1 month after participating in this study; 13) Dysnoesia, hearing disorders or limb dyskinesia; 14) The patients needed to be excluded due to some medical conditions according to the doctor.

Design outcomes

Primary

Measure	Time frame
Blood pressure;	—

Secondary

Measure	Time frame
adverse reaction;	—

Countries

China

Contacts

Public ContactZengwu Wang

fwhhc@163.com+86 010 88398070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026